# Top 200 Pharmaceutical Products by Retail Sales in 2016

**Compiled and Produced by the Njardarson Group (The University of Arizona): David T. Smith, Michael D. Delost, Haziq Qureshi, Jón T. Njarðarson**

| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 **Humira** ( Adalimumab ) abbvie $16,078 Million Immunology | 2 **Harvoni** ( Ledipasvir And Sofosbuvir ) GILEAD $9,081 Million Infectious Diseases | 3 **Revlimid** ( Lenalidomide ) Celgene $6,974 Million Oncology | 4 **Remicade** ( Infliximab ) janssen $6,966 Million Immunology | 5 **Avastin** ( Bevacizumab ) Roche $6,715 Million Oncology | 6 **Herceptin** ( Trastuzumab ) Roche $6,714 Million Oncology | 7 **Lantus** ( Insulin Glargine ) SANOFI $6,057 Million Diabetes | 8 **Enbrel** ( Etanercept ) AMGEN $5,965 Million Immunology | 9 **Rituxan** ( Rituximab ) Roche $5,765 Million Oncology | 10 **Prevnar** (Pneumococcal 7-Valent Conjugate) Pfizer $5,718 Million Anti-Bacterial | 11 **Lyrica** ( Pregabalin ) Pfizer $4,966 Million Neurological/Mental Disorders | 12 **Neulasta** ( Pegfilgrastim ) AMGEN $4,648 Million Blood Disorders | 13 **Advair** ( Salmeterol And Fluticasone Propionate ) GlaxoSmithKline $4,321 Million Respiratory Disorders | 14 **Copaxone** ( Glatiramer ) TEVA $4,223 Million Neurological/Mental Disorders | 15 **Sovaldi** ( Sofosbuvir ) GILEAD $4,001 Million Infectious Diseases | 16 **Tecfidera** ( Dimethyl Fumarate ) Biogen $3,968 Million Neurological/Mental Disorders | 17 **Januvia** ( Sitagliptin ) MERCK $3,908 Million Diabetes | 18 **Opdivo** ( Nivolumab ) Bristol-Myers Squibb $3,774 Million Oncology | 19 **Truvada** (Emtricitabine, Tenofovir Disoproxil) GILEAD $3,566 Million Infectious Diseases | 20 **Crestor** ( Rosuvastatin ) AstraZeneca $3,401 Million Cardiovascular Diseases |
| 21 **Eliquis** ( Apixaban ) Bristol-Myers Squibb $3,343 Million Blood Disorders | 22 **Gleevec** ( Imatinib ) NOVARTIS $3,323 Million Oncology | 23 **Eylea** ( Aflibercept ) REGENERON $3,323 Million Ophthalmology | 24 **Stelara** ( Ustekinumab ) janssen $3,232 Million Immunology | 25 **Spiriva** ( Tiotropium ) Boehringer Ingelheim $3,175 Million Respiratory Disorders | 26 **Gilenya** ( Fingolimod ) NOVARTIS $3,109 Million Neurological/Mental Disorders | 27 **Xarelto** ( Rivaroxaban ) Bayer $3,104 Million Cardiovascular Diseases | 28 **Symbicort** ( Budesonide And Formoterol ) AstraZeneca $2,989 Million Respiratory Disorders | 29 **Enbrel** ( Etanercept ) Pfizer $2,910 Million Immunology | 30 **Soliris** ( Eculizumab ) ALEXION $2,843 Million Blood Disorders | 31 **Victoza** ( Liraglutide ) NOVO NORDISK $2,806 Million Diabetes | 32 **Novorapid/Novolog** ( Insulin Aspart ) NOVO NORDISK $2,792 Million Diabetes | 33 **Botox** ( Onabotulinumtoxina ) ALLERGAN $2,786 Million Urology | 34 **Humalog** ( Insulin Lispro ) Lilly $2,769 Million Diabetes | 35 **Atripla** (Efavirenz, Emtricitabine, Tenofovir Disoproxil) GILEAD $2,605 Million Infectious Diseases | 36 **Zetia** ( Ezetimibe ) MERCK $2,560 Million Cardiovascular Diseases | 37 **Cialis** ( Tadalafil ) Lilly $2,472 Million Sexual Health | 38 **Levemir** ( Insulin Detemir ) NOVO NORDISK $2,392 Million Diabetes | 39 **Avonex** ( Interferon Beta-1A ) Biogen $2,314 Million Neurological/Mental Disorders | 40 **Xarelto** ( Rivaroxaban ) janssen $2,288 Million Cardiovascular Diseases |
| 41 **Alimta** ( Pemetrexed ) Lilly $2,283 Million Oncology | 42 **Xtandi** ( Enzalutamide ) Astellas $2,279 Million Oncology | 43 **Orencia** ( Abatacept ) Bristol-Myers Squibb $2,265 Million Immunology | 44 **Zytiga** ( Abiraterone Acetate ) janssen $2,260 Million Oncology | 45 **Invega** ( Paliperidone ) janssen $2,214 Million Neurological/Mental Disorders | 46 **Janumet** ( Metformin And Sitagliptin ) MERCK $2,201 Million Diabetes | 47 **Gardasil/Gardasil 9** ( HPV Vaccine ) MERCK $2,173 Million Oncology | 48 **Triumeq** ( Abacavir, Dolutegravir, Lamivudine ) GlaxoSmithKline $2,151 Million Infectious Diseases | 49 **Ibrance** ( Palbociclib ) Pfizer $2,135 Million Oncology | 50 **Aranesp** ( Darbepoetin Alfa ) AMGEN $2,093 Million Blood Disorders | 51 **Nexium** ( Esomeprazole ) AstraZeneca $2,032 Million Gastrointestinal Disorders | 52 **Vyvanse** ( Lisdexamfetamine ) Shire $2,014 Million Neurological/Mental Disorders | 53 **Tysabri** ( Natalizumab ) Biogen $1,964 Million Neurological/Mental Disorders | 54 **Stribild** (Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Disoproxil) GILEAD $1,914 Million Infectious Diseases | 55 **Prezista** ( Darunavir ) janssen $1,851 Million Infectious Diseases | 56 **Lucentis** ( Ranibizumab ) NOVARTIS $1,835 Million Ophthalmology | 57 **Imbruvica** ( Ibrutinib ) abbvie $1,832 Million Oncology | 58 **Perjeta** ( Pertuzumab ) Roche $1,828 Million Oncology | 59 **Sprycel** ( Dasatinib ) Bristol-Myers Squibb $1,824 Million Oncology | 60 **Lipitor** ( Atorvastatin ) Pfizer $1,758 Million Cardiovascular Diseases |
| 61 **Epclusa** ( Sofosbuvir And Velpatasvir ) GILEAD $1,752 Million Infectious Diseases | 62 **Simponi** ( Golimumab ) janssen $1,745 Million Immunology | 63 **Tasigna** ( Nilotinib ) NOVARTIS $1,739 Million Oncology | 64 **Lovenox** ( Enoxaparin ) SANOFI $1,734 Million Blood Disorders | 65 **Eylea** ( Aflibercept ) Bayer $1,723 Million Ophthalmology | 66 **Prograf** ( Tacrolimus ) Astellas $1,695 Million Immunology | 67 **Actemra** ( Tocilizumab ) Roche $1,680 Million Immunology | 68 **Sandostatin** ( Octreotide ) NOVARTIS $1,646 Million Oncology | 69 **Proquad** (MMRV Vaccine) MERCK $1,640 Million Infectious Diseases | 70 **Plavix** ( Clopidogrel ) SANOFI $1,637 Million Cardiovascular Diseases | 71 **Prolia** ( Denosumab ) AMGEN $1,635 Million Bone Health | 72 **Sensipar** ( Cinacalcet ) AMGEN $1,582 Million Hormonal Disorders | 73 **Hepatitis C Franchise** ( Daclatasvir ) Bristol-Myers Squibb $1,578 Million Infectious Diseases | 74 **Viagra** ( Sildenafil ) Pfizer $1,564 Million Sexual Health | 75 **Human Insulins** ( Insulin ) NOVO NORDISK $1,553 Million Diabetes | 76 **Xgeva** ( Denosumab ) AMGEN $1,529 Million Oncology | 77 **Viekira Pak** ( Ombitasvir/Paritaprevir/Ritonavir ) abbvie $1,522 Million Infectious Diseases | 78 **Afinitor/Votubia** ( Everolimus ) NOVARTIS $1,516 Million Oncology | 79 **Forteo** ( Teriparatide ) Lilly $1,500 Million Bone Health | 80 **Restasis** ( Cyclosporine ) ALLERGAN $1,488 Million Immunology |
| 81 **Genvoya** (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide) GILEAD $1,484 Million Infectious Diseases | 82 **Xolair** ( Omalizumab ) Roche $1,483 Million Immunology | 83 **Pradaxa** ( Dabigatran Etexilate ) Boehringer Ingelheim $1,468 Million Blood Disorders | 84 **Novomix/Novolog Mix** ( Biphasic Insulin Aspart ) NOVO NORDISK $1,467 Million Diabetes | 85 **Haemophilia** (Recombinant Human Coagulation Factor VIIa) NOVO NORDISK $1,466 Million Blood Disorders | 86 **Rituxan** ( Rituximab ) Roche $1,462 Million Oncology | 87 **Complera** (Rilpivirine, Emtricitabine, Tenofovir Disoproxil Fumarate) GILEAD $1,457 Million Infectious Diseases | 88 **Invokana** (Canagliflozin/Canagliflozin, Metformin HCl) janssen $1,407 Million Diabetes | 89 **Keytruda** ( Pembrolizumab ) MERCK $1,402 Million Oncology | 90 **Lucentis** ( Ranibizumab ) Roche $1,392 Million Ophthalmology | 91 **Isentress** ( Raltegravir ) MERCK $1,387 Million Infectious Diseases | 92 **Aubagio** ( Teriflunomide ) SANOFI $1,373 Million Neurological/Mental Disorders | 93 **Humulin** ( Insulin Isophane ) Lilly $1,366 Million Diabetes | 94 **Pomalyst** ( Pomalidomide ) Celgene $1,311 Million Oncology | 95 **Epogen** ( Epoetin Alfa ) AMGEN $1,282 Million Blood Disorders | 96 **Remicade** ( Infliximab ) MERCK $1,268 Million Immunology | 97 **Velcade** ( Bortezomib ) Takeda $1,252 Million Oncology | 98 **Imbruvica** ( Ibrutinib ) janssen $1,251 Million Oncology | 99 **Kogenate** ( Antihemophilic Factor (Recombinant) ) Bayer $1,236 Million Rare Diseases | 100 **Norditropin** ( Somatropin ) NOVO NORDISK $1,228 Million Hormonal Disorders |
| 101 **Velcade** ( Bortezomib ) janssen $1,224 Million Oncology | 102 **Tradjenta** ( Linagliptin ) Boehringer Ingelheim $1,196 Million Diabetes | 103 **Galvus** ( Vildagliptin ) NOVARTIS $1,193 Million Diabetes | 104 **Baraclude** ( Entecavir ) Bristol-Myers Squibb $1,192 Million Infectious Diseases | 105 **Viread** ( Tenofovir Disoproxil ) GILEAD $1,186 Million Infectious Diseases | 106 **Tivicay** ( Dolutegravir ) GlaxoSmithKline $1,182 Million Infectious Diseases | 107 **Entyvio** ( Vedolizumab ) Takeda $1,167 Million Anti-Inflammatory | 108 **Acthar** ( Corticotropin ) MALLINCKRODT $1,160 Million Autoimmune Disorders | 109 **Latuda** ( Lurasidone ) Sumitomo Dainippon Pharma $1,158 Million Neurological/Mental Disorders | 110 **Vytorin** ( Ezetimibe And Simvastatin ) MERCK $1,141 Million Cardiovascular Diseases | 111 **Cosentyx** ( Secukinumab ) NOVARTIS $1,128 Million Immunology | 112 **Mirena** ( Levonorgestrel ) Bayer $1,106 Million Sexual Health | 113 **Procrit** ( Epoetin Alfa ) janssen $1,105 Million Blood Disorders | 114 **Activase/TNKase** ( Alteplase/Tenecteplase ) Roche $1,097 Million Cardiovascular Diseases | 115 **Sutent** ( Sunitinib ) Pfizer $1,095 Million Oncology | 116 **Cubicin** ( Daptomycin ) MERCK $1,087 Million Anti-Bacterial | 117 **Vesicare** ( Solifenacin ) Astellas $1,081 Million Urology | 118 **Diovan** (Hydrochlorothiazide And Valsartan) NOVARTIS $1,073 Million Cardiovascular Diseases | 119 **Sustiva** ( Efavirenz ) Bristol-Myers Squibb $1,065 Million Infectious Diseases | 120 **Pulmicort** ( Budesonide ) AstraZeneca $1,061 Million Respiratory Disorders |
| 121 **Yervoy** ( Ipilimumab ) Bristol-Myers Squibb $1,053 Million Oncology | 122 **Leuprorelin** ( Leuprorelin ) Takeda $1,050 Million Oncology | 123 **Otezla** ( Apremilast ) Celgene $1,017 Million Dermatology | 124 **Premarin** ( Conjugated Estrogens ) Pfizer $1,017 Million Sexual Health | 125 **Micardis** ( Telmisartan ) Boehringer Ingelheim $1,017 Million Cardiovascular Diseases | 126 **Tarceva** ( Erlotinib ) Roche $1,014 Million Oncology | 127 **Tracleer** ( Bosentan ) ACTELION $1,010 Million Cardiovascular Diseases | 128 **Orkambi** ( Lumacaftor/ Ivacaftor ) VERTEX $980 Million Respiratory Disorders | 129 **Renagel/Renvela** (Sevelamer Hydrochloride, Sevelamer Carbonate) SANOFI $977 Million Urology | 130 **Ventolin** ( Albuterol ) GlaxoSmithKline $973 Million Respiratory Disorders | 131 **Abraxane** ( Paclitaxel Protein-Bound ) Celgene $973 Million Oncology | 132 **Norvasc** ( Amlodipine ) Pfizer $962 Million Cardiovascular Diseases | 133 **Exjade** ( Deferasirox ) NOVARTIS $956 Million Oncology | 134 **Infanrix, Pediarix** (Diphtheria, Tetanus Acellular, Pertussis) GlaxoSmithKline $954 Million Vaccines | 135 **Cymbalta** ( Duloxetine ) Lilly $931 Million Neurological/Mental Disorders | 136 **Xeljanz** ( Tofacitinib ) Pfizer $927 Million Immunology | 137 **Trulicity** ( Dulaglutide ) Lilly $926 Million Diabetes | 138 **Exforge** ( Amlodipine And Valsartan ) NOVARTIS $926 Million Cardiovascular Diseases | 139 **Nexavar** ( Sorafenib ) Bayer $922 Million Oncology | 140 **Singulair** ( Montelukast ) MERCK $915 Million Respiratory Disorders |
| 141 **Reyataz** ( Atazanavir ) Bristol-Myers Squibb $912 Million Infectious Diseases | 142 **Risperdal** ( Risperidone ) janssen $893 Million Neurological/Mental Disorders | 143 **Concerta** ( Methylphenidate ) janssen $863 Million Neurological/Mental Disorders | 144 **Strattera** ( Atomoxetine ) Lilly $855 Million Neurological/Mental Disorders | 145 **Abilify** ( Aripiprazole ) Otsuka $855 Million Neurological/Mental Disorders | 146 **Micardis** ( Telmisartan ) Astellas $843 Million Cardiovascular Diseases | 147 **Chantix** ( Varenicline ) Pfizer $842 Million Neurological/Mental Disorders | 148 **Brilinta** ( Ticagrelor ) AstraZeneca $839 Million Cardiovascular Diseases | 149 **Myrbetriq** ( Mirabegron ) Astellas $839 Million Renal Disorders | 150 **Farxiga** ( Dapagliflozin ) AstraZeneca $835 Million Diabetes | 151 **Xolair** ( Omalizumab ) NOVARTIS $835 Million Respiratory Disorders | 152 **Faslodex** ( Fulvestrant ) AstraZeneca $830 Million Oncology | 153 **Opsumit** ( Macitentan ) ACTELION $823 Million Cardiovascular Diseases | 154 **Kadcyla** ( Trastuzumab Emtansine ) Roche $823 Million Oncology | 155 **Lupron** ( Leuprolide Acetate ) abbvie $821 Million Oncology | 156 **Letairis** ( Ambrisentan ) GILEAD $819 Million Cardiovascular Diseases | 157 **Zoladex** ( Goserelin Acetate ) AstraZeneca $816 Million Oncology | 158 **Cerezyme** ( Imiglucerase ) SANOFI $793 Million Rare Diseases | 159 **Lialda** ( Mesalamine ) Shire $792 Million Anti-Inflammatory | 160 **Flovent** ( Fluticasone Propionate ) GlaxoSmithKline $790 Million Respiratory Disorders |
| 161 **Avodart** ( Dutasteride ) GlaxoSmithKline $787 Million Urology | 162 **Tamiflu** ( Oseltamivir ) Roche $786 Million Infectious Diseases | 163 **Betaseron** ( Interferon Beta-1B ) Bayer $778 Million Neurological/Mental Disorders | 164 **Nuvaring** (Ethinyl Estradiol And Etonogestrel) MERCK $777 Million Sexual Health | 165 **Breo Ellipta** ( Fluticasone Furoate And Vilanterol ) GlaxoSmithKline $769 Million Respiratory Disorders | 166 **Myozyme** ( Alglucosidase Alfa ) SANOFI $769 Million Rare Diseases | 167 **Simponi** ( Golimumab ) MERCK $766 Million Immunology | 168 **Neupogen** ( Filgrastim ) AMGEN $765 Million Blood Disorders | 169 **Synthroid** ( Levothyroxine ) abbvie $763 Million Hormonal Disorders | 170 **Lamictal** ( Lamotrigine ) GlaxoSmithKline $761 Million Neurological/Mental Disorders | 171 **Esbriet** ( Pirfenidone ) Roche $760 Million Idiopathic Pulmonary Fibrosis | 172 **Hepatitis** ( Vaccine ) GlaxoSmithKline $746 Million Vaccines | 173 **Toprol-XL** ( Metoprolol ) AstraZeneca $737 Million Cardiovascular Diseases | 174 **Seroquel XR** ( Quetiapine ) AstraZeneca $735 Million Neurological/Mental Disorders | 175 **Cellcept** ( Mycophenolate Mofetil ) Roche $734 Million Immunology | 176 **Celebrex** ( Celecoxib ) Pfizer $733 Million Bone Health | 177 **Pristiq** ( Desvenlafaxine ) Pfizer $732 Million Neurological/Mental Disorders | 178 **Synagis** ( Palivizumab ) abbvie $730 Million Respiratory Disorders | 179 **Creon** ( Pancrelipase ) abbvie $730 Million Rare Diseases | 180 **Votrient** ( Pazopanib ) NOVARTIS $729 Million Oncology |
| 181 **Zyprexa** ( Olanzapine ) Lilly $725 Million Neurological/Mental Disorders | 182 **Aprovel** (Irbesartan/Irbesartan, Hydrochlorothiazide) SANOFI $722 Million Cardiovascular Diseases | 183 **Kombiglyze** ( Saxagliptin/Saxagliptin, Metoprolol ) AstraZeneca $720 Million Diabetes | 184 **Yasmin** (Drospirenone And Ethinyl Estradiol) Bayer $719 Million Sexual Health | 185 **Fabrazyme** ( Agalsidase Beta ) SANOFI $714 Million Rare Diseases | 186 **Benefix** ( Coagulation Factor IX ) Pfizer $712 Million Rare Diseases | 187 **Pantoprazole** ( Pantoprazole ) Takeda $709 Million Gastrointestinal Disorders | 188 **Epzicom** ( Abacavir And Lamivudine ) GlaxoSmithKline $704 Million Infectious Diseases | 189 **Kalydeco** ( Ivacaftor ) VERTEX $703 Million Respiratory Disorders | 190 **Augmentin** ( Amoxicillin And Clavulanate ) GlaxoSmithKline $698 Million Anti-Bacterial | 191 **Kyprolis** ( Carfilzomib ) AMGEN $692 Million Oncology | 192 **Lumigan** ( Bimatoprost ) ALLERGAN $688 Million Ophthalmology | 193 **Toujeo** ( Insulin Glargine ) SANOFI $688 Million Diabetes | 194 **Erbitux** ( Cetuximab ) Lilly $687 Million Oncology | 195 **Zostavax** ( Zoster Vaccine Live ) MERCK $685 Million Infectious Diseases | 196 **Cinryze** ( Complement C1 Esterase ) Shire $680 Million Cardiovascular Diseases | 197 **Pulmozyme** ( Dornase Alfa ) Roche $678 Million Rare Diseases | 198 **Synagis** ( Palivizumab ) AstraZeneca $677 Million Respiratory Disorders | 199 **Ranexa** ( Ranolazine ) GILEAD $677 Million Cardiovascular Diseases | 200 **Androgel** ( Testosterone ) abbvie $675 Million Hormonal Disorders |